Mon, March 26, 2018
Fri, March 23, 2018
Thu, March 22, 2018
Wed, March 21, 2018
Tue, March 20, 2018
Mon, March 19, 2018
Fri, March 16, 2018
Thu, March 15, 2018
Wed, March 14, 2018
Tue, March 13, 2018
Mon, March 12, 2018
Fri, March 9, 2018
Thu, March 8, 2018
Wed, March 7, 2018
Tue, March 6, 2018
Mon, March 5, 2018
Fri, March 2, 2018

Anupam Rama Maintained (SRPT) at Buy with Increased Target to $95 on, Mar 14th, 2018


//stocks-investing.news-articles.net/content/201 .. ith-increased-target-to-95-on-mar-14th-2018.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


Anupam Rama of JP Morgan, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Increased Target from $75 to $95 on, Mar 14th, 2018.

Anupam has made no other calls on SRPT in the last 4 months.



There are 5 other peers that have a rating on SRPT. Out of the 5 peers that are also analyzing SRPT, 0 agree with Anupam's Rating of Hold.



These are the ratings of the 5 analyists that currently disagree with Anupam


  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $100 on, Tuesday, March 13th, 2018
  • Joseph Schwartz of "Leerink Swann" Maintained at Buy with Increased Target to $92 on, Tuesday, March 13th, 2018
  • Debjit Chattopadhyay of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $92 on, Monday, March 12th, 2018
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $64 on, Tuesday, March 6th, 2018
  • Yun Zhong of "Janney Montgomery Scott" Initiated at Strong Buy and Held Target at $75 on, Thursday, January 4th, 2018

Publication Contributing Sources